Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LAROTRECTINIB Cause Multiple organ dysfunction syndrome? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Multiple organ dysfunction syndrome have been filed in association with LAROTRECTINIB (VITRAKVI). This represents 0.6% of all adverse event reports for LAROTRECTINIB.

5
Reports of Multiple organ dysfunction syndrome with LAROTRECTINIB
0.6%
of all LAROTRECTINIB reports
4
Deaths
3
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From LAROTRECTINIB?

Of the 5 reports, 4 (80.0%) resulted in death, 3 (60.0%) required hospitalization.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LAROTRECTINIB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does LAROTRECTINIB Cause?

Fatigue (56) Drug ineffective (52) Dizziness (50) Death (48) Pain (42) Neuropathy peripheral (39) Nausea (32) Off label use (31) Disease progression (27) Malignant neoplasm progression (23)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which LAROTRECTINIB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

LAROTRECTINIB vs LASILIX LAROTRECTINIB vs LASIX LAROTRECTINIB vs LASMIDITAN LAROTRECTINIB vs LATANOPROST LAROTRECTINIB vs LATANOPROSTENE BUNOD

Related Pages

LAROTRECTINIB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome LAROTRECTINIB Demographics